FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030557181> ?p ?o ?g. }

• W3030557181 abstract "e15271 Background: Clinical trials with oncolytic viruses for cancer treatment have shown limited efficacy due to viruses’ rapid clearance by patients’ innate and adaptive immune systems. In a recent first-in-human clinical trial, we confirmed the safety and feasibility of our approach to enhance oncolytic vaccinia virus (OVV) delivery and improve tumor targeting by utilizing an autologous cell-based cell delivery system (auto-OVV). We also developed an allogeneic cell-based platform (SuperNova1c - SNV1c) aiming to protect and potentiate OVV’s antitumor effects in large patient populations. Methods: We evaluated the immunomodulatory potential of auto-OVV by an extensive time-course analysis of cytokines in patients’ plasma (Luminex profiling) and peripheral blood immune cells (flow cytometry). We also analyzed the ability of SNV1c to protect the OVV from antibody/complement inactivation in vitro and in vivo following intratumoral injection in various mouse tumors. The immune cell infiltrations of the injected tumors were also analyzed. Results: Therapy with auto-OVV induced a coordinated activation of cytokine, T cell and NK responses in patients as early as 1 day, peaking around 1-week and lasting for up to 1-month post treatment. Effective OVV amplification in cancer patients correlated with significant changes of multiple innate and adaptive immune parameters. Patient stratification into groups with transient versus persistent viral DNA was linked to opposing and mutually exclusive patterns of robust activation of NK versus T cell responses, respectively. SNV1c showed significantly enhanced protection of OVV in vitro and led to statistically significant tumor growth inhibition as compared to control non-treated tumors or to naked OVV-treated tumors. Importantly, local administration of SNV1c induced systemic therapeutic effects. Five days after SNV1c administration, tumor infiltrating lymphocytes from both treated and untreated tumors showed increased CD4 and CD8 T-cell infiltrations, decreased Tregs, and improved effector to Treg ratios, associated with tumor growth inhibition at both treated and untreated tumor sites. Conclusions: This study establishes the timeline of treatment-related immunological changes and identifies potential immunological correlates associated with the OVV persistence in vivo. We also demonstrate the ability of our cell-based platforms to protect and potentiate OVV by circumventing innate and adaptive immune barriers, resulting in enhanced oncolytic virotherapy." @default.
• W3030557181 created "2020-06-05" @default.
• W3030557181 creator A5005447923 @default.
• W3030557181 creator A5026953370 @default.
• W3030557181 creator A5058865732 @default.
• W3030557181 creator A5059941996 @default.
• W3030557181 creator A5062153159 @default.
• W3030557181 creator A5065135993 @default.
• W3030557181 creator A5089573357 @default.
• W3030557181 date "2020-05-20" @default.
• W3030557181 modified "2023-09-27" @default.
• W3030557181 title "Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms." @default.
• W3030557181 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e15271" @default.
• W3030557181 hasPublicationYear "2020" @default.
• W3030557181 type Work @default.
• W3030557181 sameAs 3030557181 @default.
• W3030557181 citedByCount "0" @default.
• W3030557181 crossrefType "journal-article" @default.
• W3030557181 hasAuthorship W3030557181A5005447923 @default.
• W3030557181 hasAuthorship W3030557181A5026953370 @default.
• W3030557181 hasAuthorship W3030557181A5058865732 @default.
• W3030557181 hasAuthorship W3030557181A5059941996 @default.
• W3030557181 hasAuthorship W3030557181A5062153159 @default.
• W3030557181 hasAuthorship W3030557181A5065135993 @default.
• W3030557181 hasAuthorship W3030557181A5089573357 @default.
• W3030557181 hasConcept C104317684 @default.
• W3030557181 hasConcept C136449434 @default.
• W3030557181 hasConcept C1491633281 @default.
• W3030557181 hasConcept C203014093 @default.
• W3030557181 hasConcept C2777701055 @default.
• W3030557181 hasConcept C2777760223 @default.
• W3030557181 hasConcept C2781356689 @default.
• W3030557181 hasConcept C40767141 @default.
• W3030557181 hasConcept C502942594 @default.
• W3030557181 hasConcept C54355233 @default.
• W3030557181 hasConcept C553184892 @default.
• W3030557181 hasConcept C55493867 @default.
• W3030557181 hasConcept C71924100 @default.
• W3030557181 hasConcept C82210918 @default.
• W3030557181 hasConcept C86803240 @default.
• W3030557181 hasConcept C8891405 @default.
• W3030557181 hasConceptScore W3030557181C104317684 @default.
• W3030557181 hasConceptScore W3030557181C136449434 @default.
• W3030557181 hasConceptScore W3030557181C1491633281 @default.
• W3030557181 hasConceptScore W3030557181C203014093 @default.
• W3030557181 hasConceptScore W3030557181C2777701055 @default.
• W3030557181 hasConceptScore W3030557181C2777760223 @default.
• W3030557181 hasConceptScore W3030557181C2781356689 @default.
• W3030557181 hasConceptScore W3030557181C40767141 @default.
• W3030557181 hasConceptScore W3030557181C502942594 @default.
• W3030557181 hasConceptScore W3030557181C54355233 @default.
• W3030557181 hasConceptScore W3030557181C553184892 @default.
• W3030557181 hasConceptScore W3030557181C55493867 @default.
• W3030557181 hasConceptScore W3030557181C71924100 @default.
• W3030557181 hasConceptScore W3030557181C82210918 @default.
• W3030557181 hasConceptScore W3030557181C86803240 @default.
• W3030557181 hasConceptScore W3030557181C8891405 @default.
• W3030557181 hasLocation W30305571811 @default.
• W3030557181 hasOpenAccess W3030557181 @default.
• W3030557181 hasPrimaryLocation W30305571811 @default.
• W3030557181 hasRelatedWork W12181843 @default.
• W3030557181 hasRelatedWork W14743255 @default.
• W3030557181 hasRelatedWork W15149476 @default.
• W3030557181 hasRelatedWork W15564899 @default.
• W3030557181 hasRelatedWork W17404775 @default.
• W3030557181 hasRelatedWork W18323488 @default.
• W3030557181 hasRelatedWork W20970074 @default.
• W3030557181 hasRelatedWork W5578011 @default.
• W3030557181 hasRelatedWork W5786138 @default.
• W3030557181 hasRelatedWork W7420362 @default.
• W3030557181 isParatext "false" @default.
• W3030557181 isRetracted "false" @default.
• W3030557181 magId "3030557181" @default.
• W3030557181 workType "article" @default.